Patent application number | Description | Published |
20080214499 | Lipid-Regulating Agent and Use Thereof - The object of the present invention is to provide a lipid-regulating agent or a composition for regulating the amount of lipids comprising the agent. The present invention solves the above object by providing a lipid-regulating agent comprising a cyclic tetrasaccharide and/or its saccharide-derivative(s) and a composition for regulating the amount of lipids comprising the lipid-regulating agent. | 09-04-2008 |
20080241904 | PROCESS FOR PRODUCING ISOMALTOSE AND USES THEREOF - A novel process for producing isomaltose and uses thereof and comprising the steps of contacting saccharides, which have a glucose polymerization degree of at least two and α-1,4 glucosidic linkage as a linkage at the non-reducing end, with an α-isomaltosylglucosaccharide-forming enzyme, in the presence or the absence of α-isomaltosyl-transferring enzyme to form a-isomaltosylglucosaccharides, which have a glucose polymerization degree of at least three, α-1,6 glucosidic linkage as a linkage at the non-reducing end, and α-1,4 glucosidic linkage as a linkage other than the non-reducing end, and/or to form cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1″3)-α-D-glucopyranosyl-(1→}; contacting the saccharides so formed with isomaltose-releasing enzyme to release isomaltose; and collecting the released isomaltose; and uses thereof. | 10-02-2008 |
20090022872 | HIGHLY-BRANCHED STARCH, ITS PRODUCTION AND USES - An object of the present invention is to provide a novel starchy substance having a retrogradation-resistance, a process for producing the starchy substance efficiently from a material starch by enzymatic reaction, and uses thereof. The present invention attains the above object by providing branched starch having 6-α-maltosyl- and/or 6-α-maltotetraosyl-structure(s) with a marked retrogradation-resistance, a process for producing the branched starch without lowering the molecular weight of material starch, and uses thereof. | 01-22-2009 |
20090023684 | FLUID FOR PERITONEAL DIALYSIS - The present invention has an object to provide a fluid for peritoneal dialysis with satisfactory body fluid removability, high biocompatibility, and improved storage stability, and the object is attained by a fluid for peritoneal dialysis containing one or more saccharides selected from cyclonigerosylnigerose, cyclomaltosylmaltose, and L-ascorbic acid 2-glucoside. | 01-22-2009 |
20100015671 | CYCLIC MALTOSYLMALTOSE, CYCLIC MALTOSYMALTOSE-FORMING ENZYME, THEIR PREPARATION AND USES - An object of the present invention is to provide an option of non-reducing saccharide by providing a novel non-reducing saccharide composed of glucose as constituents and to provide a novel enzyme forming the non-reducing saccharide, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the non-reducing saccharide, and uses thereof. The present invention solves the above object by providing a novel cyclic saccharide having a structure of cyclo{>6)-α-D-glucopyranosyl-(1>4)-α-D-glucopyranosyl-(1>6)-α-D-glucopyranosyl-(1>4)-α-D-glucopyranosyl-(1>}, cyclic maltosylmaltose, novel cyclic maltosylmaltose-forming enzyme, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the cyclic maltosylmaltose or a saccharide composition comprising the same, and uses thereof. | 01-21-2010 |
20100120710 | Branched alpha-glucan, alpha-glucosyltransferase which forms the glucan, their preparation and uses - The present invention has objects to provide a glucan useful as water-soluble dietary fiber, its preparation and uses. The present invention solves the above objects by providing a branched α-glucan, which is constructed by glucose molecules and characterized by methylation analysis as follows:
| 05-13-2010 |
20100143389 | IMMUNOMODULATING AGENT IN GUT - An object of the present invention is to provide an immunomodulating agent in gut that can be ingested continuously in daily diet without adverse side effect. The object is attained by providing an immunomodulating agent in gut comprising a cyclic tetrasaccharide as an effective ingredient. | 06-10-2010 |
20100285562 | ISOCYCLOMALTOOLIGOSACCHARIDE(S), ISOCYCLOMALTOOLIGOSACCHARIDE-FORMING ENZYME, THEIR PREPARATION AND USES - A non-reducing saccharide by providing a novel non-reducing saccharide composed of glucose as constituents, a novel enzyme forming the non-reducing saccharide, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the non-reducing saccharide, and uses thereof are provided by use of an isocyclomaltooligosaccharide(s) having a structure represented by Formula 1, | 11-11-2010 |
20110045137 | METHOD FOR INHIBITING COLORING OF A SYRUPY SWEETENER COMPRISING A NON-REDUCING OLIGOSACCHARIDE HAVING A BETA-FRUCTOFRANOSIDIC LINKAGE AND A REDUCING SACCHARIDE, AND USE THEREOF - The objects of the present invention are to provide a method for inhibiting the coloration of a syrupy sweetener, comprising a reducing saccharide together with a non-reducing oligosaccharide having a β-fructofuranosidic linkage, without deteriorating the taste inherent to the syrupy sweetener; and to provide a syrupy sweetener, comprising a reducing saccharide together with a non-reducing oligosaccharide having a β-fructofuranosidic linkage, which is stabilized by the method. The present invention attains the above objects by providing a method for inhibiting the coloring of a syrupy sweetener, comprising a reducing saccharide together with a non-reducing oligosaccharide having a β-fructofuranosidic linkage, which comprises a step of incorporating a lactate into the syrupy sweetener, and by providing a syrupy sweetener, comprising a reducing saccharide together with a non-reducing oligosaccharide having a β-fructofuranosidic linkage, which is stabilized by the method. | 02-24-2011 |
20110091726 | PARTICULATE COMPOSITION CONTAINING ANHYDROUS CRYSTALLINE 2-O-alpha-D-GLUCOSYL-L-ASCORBIC ACID, PROCESS FOR PRODUCING THE SAME, AND USES THEREOF - The present invention aims to provide a particulate composition containing anhydrous crystalline 2-O-α-D-glucosyl-L-ascorbic acid having a significantly, hardly solidifiable property compared to conventional ones in a grade for use in quasi-drugs; a process for producing the same; and uses thereof. The present invention solves the above object by providing a particulate composition containing anhydrous crystalline 2-O-α-D-glucosyl-L-ascorbic in an amount of over 98.0% by weight but less than 99.9% by weight, on a dry solid basis; or a degree of crystallinity of 90% or higher for anhydrous crystalline 2-O-α-D-glucosyl-L-ascorbic acid, when calculated based on a profile of powder X-ray diffraction analysis of the particulate composition, and a dynamic vapor sorption level of 0.01% by weight or lower, when kept at 25° C. under a relative humidity of 35% by weight for 12 hours after removal water in the particulate composition under nitrogen gas stream; and by providing a process for producing the same and uses thereof. | 04-21-2011 |
20110091968 | MONOCLONAL ANTIBODY SPECIFIC TO BOTH HUMAN INTERFERON-ALPHA SUBTYPE ALPHA 8 AND ITS MUTANT PROTEINS - The present invention has the first object to provide a monoclonal antibody specific to interferon α subtype α8 (IFNα8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFNα8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFNα8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8. The present invention solves the above objects by providing a monoclonal antibody specific to IFNα8 and its mutant proteins, a hybridoma capable of producing the monoclonal antibody, a method for detecting the IFNα8 and its mutant proteins by immunoreaction using the monoclonal antibody, a method for purifying the IFNα8 and its mutant proteins using the monoclonal antibody, and a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8, which contains the monoclonal antibody as an effective ingredient. | 04-21-2011 |
20110251657 | LIGHTING DEVICE - The aims of the present invention are to provide a lighting device, which can be used as illumination for ordinary life space, and has the functions of activating human serotonin nervous system, substantially not raising noradrenaline level in blood, decreasing aggressiveness, and reducing the factors that induce so-called “kireru” state. The aims are attained by providing a lighting device which radiates light containing near ultraviolet radiation having a wavelength in the range of 320 nm to 380 nm along with visible light. | 10-13-2011 |
20120035187 | ANTI-NEURODEGENERATIVE DISEASE AGENT - The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1: | 02-09-2012 |
20120040407 | CELLOBIOSE 2-EPIMERASE, ITS PREPARATION AND USES - The present invention has objects to provide a thermostable cellobiose 2-epimerase, its preparation and uses. The present invention attains the above objects by providing a thermostable cellobiose 2-epimerase, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a process for producing the enzyme, and a process for producing isomerized saccharides using the enzyme. | 02-16-2012 |
20120196331 | HIGHLY-BRANCHED STARCH, ITS PRODUCTION AND USES - An object of the present invention is to provide a novel starchy substance having a retrogradation-resistance, a process for producing the starchy substance efficiently from a material starch by enzymatic reaction, and uses thereof. The present invention attains the above object by providing branched starch having 6-α-maltosyl- and/or 6-α-maltotetraosyl-structure(s) with a marked retrogradation-resistance, a process for producing the branched starch without lowering the molecular weight of material starch, and uses thereof. | 08-02-2012 |
20120329098 | CELLOBIOSE 2-EPIMERASE, ITS PREPARATION AND USES - The present invention has objects to provide a thermostable cellobiose 2-epimerase, its preparation and uses. The present invention attains the above objects by providing a thermostable cellobiose 2-epimerase, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a process for producing the enzyme, and a process for producing isomerized saccharides using the enzyme. | 12-27-2012 |
20130165399 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT - The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient. | 06-27-2013 |
20130295618 | PROCESS FOR PRODUCING A PARTICULATE COMPOSITION COMPRISING ANHYDROUS CRYSTALLINE 2-O-ALPHA-D-GLUCOSYL-L-ASCORBIC ACID - The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside. | 11-07-2013 |
20130309188 | EXTERNAL PREPARATION FOR SKIN - The present invention has an object to provide an external dermal agent with a sustainable anti-wrinkle action, which has both the action of enhancing the proliferation and differentiation of keratinocytes in the skin and the action of enhancing the collagen production in the skin, and which assists the maintenance and the improvement of tissue structures and physiological functions of the epidermis and the dermis, whereby providing a remarkable skin improvement effect. The present invention solves the above abject by providing an external dermal agent containing α-D-glucopyranosyl-(1→3′)-adenosine and/or α-D-glucopyranosyl-(1→5′)-adenosine as an effective ingredient(s). | 11-21-2013 |
20140148409 | FLUID FOR PERITONEAL DIALYSIS - The present invention has an object to provide a fluid for peritoneal dialysis with satisfactory body fluid removability, high biocompatibility, and improved storage stability, and the object is attained by a fluid for peritoneal dialysis containing one or more saccharides selected from cyclonigerosylnigerose, cyclomaltosylmaltose, and L-ascorbic acid 2-glucoside. | 05-29-2014 |
20140178943 | PROCESS FOR PRODUCING A PARTICULATE COMPOSITION COMPRISING ANHYDROUS CRYSTALLINE 2-O-ALPHA-D-GLUCOSYL-L-ASCORBIC ACID - The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside. | 06-26-2014 |
20140315849 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT - The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient. | 10-23-2014 |
20140348922 | PROCESS FOR PRODUCING A PARTICULATE COMPOSITION COMPRISING AN HYDROUS CRYSTALLINE 2-O-ALPHA-D-GLUCOSYL-L-ASCORBIC ACID - The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside. | 11-27-2014 |